Skip to main content
. 2022 Apr 14;21(3):e184–e187. doi: 10.1016/j.jcf.2022.04.004

Fig. 1.

Fig 1

SARS-CoV-2 neutralizing – receptor binding domain antibodies (%) in cystic fibrosis (CF) patients (n = 33) and in healthy controls (Ctl) (n = 66), 20 days after vaccination with the first dose and one month after the second dose of the BNT162b2 vaccine. Black lines represent median (IQR) values. CF: cystic fibrosis, Ctl: control.